07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Amicus Therapeutics, GlaxoSmithKline deal

Amicus and GlaxoSmithKline amended a 2010 deal that gave the pharma exclusive, worldwide rights to Amicus' Fabry's disease therapy migalastat. Amicus will now be responsible for U.S. commercialization of migalastat as monotherapy, in combination with...
07:00 , Jul 23, 2012 |  BioCentury  |  Finance

Amicable for Amicus

Amicable for Amicus Orphan disease play Amicus Therapeutics Inc. (NASDAQ:FOLD) gave up potential milestone payments from partner GlaxoSmithKline plc last week and assumed more development costs in exchange for U.S. commercial rights in their Fabry's...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Amicus Therapeutics, JCR Pharmaceuticals, GlaxoSmithKline preclinical data

In mice, Amigal migalastat co-formulated with JR-051 significantly reduced globotriaosylceramide (GL-3) levels in the heart and kidneys vs. JR-051 alone. Details were not disclosed. Accumulation of GL-3 causes various symptoms of Fabry's disease, including pain,...
01:48 , Jul 18, 2012 |  BC Extra  |  Company News

GSK, Amicus amend Fabry's disease deal

Amicus Therapeutics Inc. (NASDAQ:FOLD) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) amended a 2010 deal that gave the pharma exclusive, worldwide rights to Amicus' Fabry's disease therapy migalastat. Amicus will now be responsible for U.S. commercialization of...
07:00 , Mar 12, 2012 |  BioCentury  |  Product Development

Replacing the replacements

GlaxoSmithKline plc is planning to use peptide technology from Angiochem Inc. to develop next-generation enzyme replacement therapies that target the CNS without lessening their effects in the periphery. They could replace current drugs that address...
07:00 , Nov 1, 2010 |  BioCentury  |  Strategy

Orphans by Algorithm

GlaxoSmithKline plc is taking a stepwise approach to building its new rare diseases unit that for now is relying heavily on external collaborations and in-licensing as a source of late-stage compounds. Last week, GSK licensed...